INTRODUCTION
Platelet-activating factor (PAF)' is a potent chemical mediator released from antigen-stimulated, IgE-senReceived for publication 20 April 1982 and in revised form 20 July 1982.
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sitized basophils (1) (2) (3) and from human neutrophils after exposure to phagocytable particles (4) . Recently the structure of PAF was identified as 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine or AGEPC (5).
AGEPC stimulates, by both thromboxane A2-dependent and--independent pathways, platelet aggregation in rabbit and human platelet preparations (5) (6) (7) (8) . The intravenous injection of AGEPC into rabbits or baboons results in a transient thrombocytopenia and leukopenia, which is associated with a prolonged hypotensive period (9) . AGEPC also exhibits powerful anti-hypertensive properties in rats, by an as yet undetermined mechanism (10) . In human polymorphonuclear. leukocytes (PMN) , AGEPC and various analogues stimulate leukocyte aggregation (11), degranulation, and chemotaxis (12) .
Another chemical mediator synthesized by PMN is (5S,6Z,8E,1OE,12R,14Z)-5,12-dihydroxyeicosa-6,8,10,14-tetraenoic acid or LTB4 (13) . LTB4 is also a potent inducer of leukocyte aggregation, degranulation, and chemotaxis (14) (15) (16) (17) (18) . Using desensitization experiments, conflicting evidence has appeared concerning the relationship(s) between AGEPC and hydroxy acid derivatives of arachidonic acid (19, 20 In experiments where LTB4 and 5S,12S diHETE were separated, the same column was used, but an isocratic system of acetonitrile:water:acetic acid (65:35:0.1; 1.0 ml/min) was used for elution. Detection was at 280 nm with both systems using a Tracor model 970A detector (Tracor Analytic, Elk Grove Village, IL).
GC/MS. Reactions were stopped by the addition of onehalf volume of acetone, acidified to pH 4.0 with H3PO4, passed through a C18, reverse phase Sep-Pak (Waters Associates), and sequentially washed with 10 ml H20, 10 ml hexane, and eluted with 10 ml ethyl acetate. The samples were concentrated under N2'and purified by RP-HPLC as above. After lyophilization, the sample was dissolved in ether-methanol (9:1), esterified with diazomethane, and derivatized for GC/MS as previously described (24) . GC/MS analysis was done on a Hewlett Packard model 5992 spectrometer (Hewlett-Packard Co., Palo Alto, CA) operated in the selective ion monitoring (SIM) mode. The column was a 6-ft, 1% SE-30 heated initially to 220°C; the temperature was raised linearly at 2°C/min up to 250°C. The injection port was at 250°C, the helium flow was 25 ml/min, and fragments mass/electron (m/e) 203, 293, and 383 were continuously monitored.
Metabolism of [1-'4C]arachidonic acid. Human neutrophil arachidonic acid metabolism was monitored using a slight modification of previously published methods (25) . Before 
RESULTS
Incubation of human PMN with 9 to 1800 nM AGEPC results in a concentration-dependent stimulation of neutrophil aggregation. Aggregation is maximal within 2 min, and the rate of spontaneous recovery is inversely related to the concentration of AGEPC (Fig. 1A) . Generally, even the highest concentrations of AGEPC demonstrate reversible aggregation within 15 min (data not shown).
AGEPC-induced neutrophil aggregation is inhibited in a concentration-dependent manner by ETYA and NDGA, two agents that retard arachidonate lipoxygenation in neutrophils (27) . The 50% inhibitory concentration (IC50) for both inhibitors is about 10 ,M ( Table I ). The cyclooxygenase inhibitor indomethacin is a less effective inhibitor of AGEPC-induced neutrophil aggregation, with an IC50 of -100 gM (Table I) .
Another potent stimulator of human PMN aggregation is LTB4 (19) . Like AGEPC, LTB4 stimulates neutrophil aggregation in a concentration-dependent manner. The aggregation is again maximal within 2 min, and the rate of disaggregation is inversely related to the concentration of LTB4 (Fig. IB) . Although ---\ 9-.97 nnM
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.j. ,r-. Human neutrophils (2.5 X 106/ml) were incubated at 37°C for 5 min with or without the various inhibitors of arachidonic acid metabolism at the indicated concentrations. The neutrophils were then challenged with either 180 nM AGEPC or 2.97 nM LTB4. Data are presented as the mean±SEM of three separate determinations. All determinations were made at the nadir of the agonist response.
a P < 0.05.
AGEPC and LTB4 display qualitatively similar aggregation curves, LTB4 is, on a molar basis, 10-100 times more potent than AGEPC (Fig. 1, A and B) . Unlike AGEPC-induced aggregation, LTB4-mediated aggregation is not inhibited in a concentration dependent manner by ETYA (Table I) . As great a concentration as 100 uM ETYA is not effective. NDGA does significantly inhibit LTB4-induced aggregation at 30 uM, but no inhibition is observed at 3 or 10 ,uM (Table I) Fig. 2 , we stimulated human neutrophils with 900 nM AGEPC, collected peak "X" from the RP-HPLC, and derivatized the sample for GC/MS as described in Methods. Authentic derivatized LTB4 has a retention time of 6.3 min on our gas chromatograph. Peak "X" also has a retention time of 6.3 min under these conditions, and as shown in Fig. 3 , displayed prominant ions at m/e 203 mass ion (M+)-(111 + 180), 293 M+-(lll + 90), and 383 M -(111), which are all indicative of authentic LTB4 and confirm that peak "X" is indeed LTB4 (Fig. 3 ).
An estimate of the rate of synthesis of 5-HETE and LTB4 in response to AGEPC was obtained from neutrophils prelabeled with [1-_4C]arachidonic acid. A measurable increase in 5-HETE and LTB4 biosynthesis above unstimulated levels was observed 20 s after the addition of 900 nM AGEPC, and continued to increase through 90 s, the last time point measured (Table II) . In all cases, the amount of 5-HETE synthesized was less than the amount of LTB4, but 5-HETE synthesis did parallel LTB4 biosynthesis (Table II) .
If AGEPC-induced neutrophil aggregation is mediated by LTB4, there should be some evidence of cross-desensitization. We find that neutrophils preincubated with 1.8 uM AGEPC are desensitized equally well to subsequent challenge with AGEPC or LTB4 (Table III) . However, cells preincubated with 87.0 nM LTB4 are more refractory to a second stimulation with 8.7 nM LTB4 than to 180 nM AGEPC (Table III) (9), until recently little information has emerged concerning the mechanism of action of AGEPC in neutrophils. An analysis of AGEPC-and LTB4-stimulated neutrophil aggregation suggests that these two agonists have qualitatively similar aggregation curves, but LTB4 is, on a molar basis, 10-100 times more potent than AGEPC (Fig. 1, A and B) . If AGEPC-induced aggregation is mediated by LTB4, blockers of LTB4 biosynthesis should be more effective inhibitors of AGEPC-induced aggregation than LTB4-mediated aggregation. This is precisely what we found-ETYA and NDGA are potent inhibitors of AGEPC-induced aggregation, but much less effective when tested against LTB4.
Paradoxically, indomethacin, the cyclooxygenase inhibitor, also could inhibit AGEPC, and to a lesser extent LTB4-induced neutrophil aggregation. However, indomethacin is effective at concentrations 10-100 times greater than required to inhibit all prostaglandin biosynthesis (28) .
These data with ETYA, NDGA, and indomethacin correlate well with the observations of Doig and FordHutchinson (29) , which show that aggregation induced by the Ca21 ionophore A-23187 (indirectly through LTB4 synthesis) is inhibited by ETYA and NDGA, but (31), and interfere with the binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to neutrophils (32) . ETYA can also inhibit FMLP binding to neutrophils (33) . Certainly some of the paradoxical activities of these compounds may be explained by mechanisms other than inhibition of arachidonate 5-lipoxygenation. Because of the lack of specificity of the available inhibitors, in order to directly associate AGEPC-induced neutrophil aggregation with LTB4, physical proof of LTB4 synthesis in response to AGEPC is required. Our RP-HPLC experiments show that an unknown peak, "X", with the approximate retention time of LTB4, appears in chromatograms from neutrophils exposed to AGEPC, and that the synthesis of peak "X" is inhibited by 30 uM NDGA. Subsequent GC/ MS analysis confirmed without equivocation that peak "X" is indeed LTB4 with prominant ions at m/e 203, 293, and 383.
Because LTB4 and 5S,12S diHETE coelute in our RP-HPLC system, we also repeated the above experiments using an acetonitrile:water:acetic acid system as outlined in Methods. This system resolves LTB4 and 5S,12S diHETE, but we found no evidence of 5S,12S diHETE synthesis in response to AGEPC (data not shown).
It is tempting to speculate that AGEPC-induced neutrophil aggregation is mediated by subsequent LTB4 biosynthesis. For (25, 27) .
A final link between LTB4 and AGEPC is observed in the desensitization experiments. We observe both homologous and heterologous desensitization with LTB4 and AGEPC. AGEPC desensitizes subsequent AGEPC-or LTB4-induced aggregation equally well, but LTB4 desensitizes subsequent LTB4-induced aggregation more readily than subsequent AGEPC-induced aggregation. These data agree with the experiments of O'Flaherty et al. (20) , who found essentially the same degree of crossover between the two agonists. However, our data do not agree with the data of FordHutchinson (19) , who found no evidence of cross-desensitization between AGEPC and LTB4. The reason(s) for this discrepancy is not known, but different conditions and species were used. Because preincubation of neutrophils with LTB4 only desensitizes '40% of the subsequent AGEPC response, the possibility does remain that part of the AGEPC response is independent of LTB4.
When neutrophils are stimulated, several other 5-lipoxygenase products are produced (13, 27) . However, we feel that LTB4 is the principal pro-aggregatory species in our system. LTB4 in our hands is 10 to 100 times more potent than 5S,12S-diHETE, 100 to 1,000 times more potent than 5-HETE, and >1,000 times more potent than 12-HETE. Very similar potency relationships have been previously established by others (34, 35) .
The elaboration of LTB4 and other 5-lipoxygenase products is clearly becoming of general importance in leukocyte physiology. LTB4 biosynthesis has been associated with serum-coated zymosan and FMLP-stimulation of neutrophil function (36, 37) , and while this paper was under review, indirect radiolabel evidence of LTB4 synthesis in rabbit AGEPC-stimulated neutrophils appeared (25) .
It may be that other biological activities of AGEPC are also mediated by leukotrienes and/or other products of arachidonic acid metabolism. However, regardless of the amount of indirect evidence accumulated, until selective 5-lipoxygenase inhibitors and/or receptor-level antagonists of LTB4 become available, an absolute functional link between AGEPC, LTB4, and any physiological system cannot be established. At this time we can state that both AGEPC and LTB4 stimulate neutrophil aggregation, and that AGEPC does initiate the synthesis of levels of LTB4 that are sufficient to account for the AGEPC response.
